XconomyFormer Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy MergerTheStreet.comOnce the merger is complete in the third quarter, the combined companies will take the Alpine Immune Sciences name and focus on its pipel… Continue reading
Global Cancer Immunotherapy Report 2017: Building on Initial Successes to Improve Clinical Outcomes – Research …Yahoo FinanceNevertheless, metastatic melanoma remains incurable. Furthermore, in many studies in advanced melanoma and other cancers, onl… Continue reading
Chemical & Engineering News (subscription) |
CRISPR pioneer Jennifer Doudna shares her outlook for the groundbreaking gene-editing tool
Chemical & Engineering News (subscription) Inspiration for cracking the CRISPR code: My dad was not a scientist, but he loved solving puzzles. One of his favorites was cryptoquotes—quotes by famous people that are encrypted. The challenge is to break the code and solve the quote. They would … |
Harvard Gazette |
Researchers study secrets of aging via stem cells
Harvard Gazette If stem cells offer potential solutions, they’re also part of the problem. Stem cells, which can differentiate into many cell types, are important parts of the body’s repair system, but lose regenerative potency as we age. In addition, their self … New cocktail encourages stem cell diversificationLab News Delving into Stem Cell Research and its Potential 2017 – Research and MarketsYahoo Finance Plasticell to produce red blood cell substitute from pluripotent stem cellsDrug Target Review Medgadget (blog) –WhaTech all 9 news articles » |
Controlled Environments Magazine |
Nanoparticles Reprogram Immune Cells to Battle Cancer
Controlled Environments Magazine Researchers have developed strategies to rewire T cells’ genetics so that certain cancer cells pop up on their radar as dangerous. One class of engineered T cells is known as CAR T cells, for the researcher-designed chimeric antigen receptors encoded … |
|
Immunotherapy for GU Ca: A primer for urologists
ModernMedicine Immunotherapy for genitourinary malignancies is not new, as high-dose interleukin-2 (IL-2 [Proleukin]) for metastatic renal cell carcinoma (mRCC) and intravesical bacillus Calmette-Guérin for high-grade bladder cancer have been used since the 1990s. |
|
Immunotherapy for GU Ca: A primer for urologists
ModernMedicine Immunotherapy for genitourinary malignancies is not new, as high-dose interleukin-2 (IL-2 [Proleukin]) for metastatic renal cell carcinoma (mRCC) and intravesical bacillus Calmette-Guérin for high-grade bladder cancer have been used since the 1990s. |
|
Cellular Dynamics, Stemcell Technologies Ink iPSC Distribution …
GenomeWeb Under the terms of the deal, Stemcell will distribute Cellular Dynamics’ iCell line of induced pluripotent stem cell products. Cellular Dynamics International Signs Distribution Deal with …Business Wire (press release) |